328918-26-9

Upstream product

• 42806-90-6 2-(4-hydroxyphenoxy)-2-methyl propionic acid ethyl ester 
• 518343-95-8 2-(4-{3-[(biphenyl-4-carbonyl)amino]-4-oxo-pentyloxy}-phenoxy)-2-methyl-propionic acid 
• 328918-88-3 2-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid ethyl ester 
• 328918-86-1 toluene-4-sulfonic acid 2-(2-biphenyl-4-yl-5-methyloxazol-4-yl)ethyl ester 
• 328918-85-0 2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethanol 
• 328918-82-7 2-(4-bromophenyl)-5-methyl-4-oxazoleacetic acid 
• 328918-84-9 2-(4-bromophenyl)-5-methyl-4-oxazoleethanol 
• 328918-83-8 [2-(4-bromophenyl)-5-methyloxazole-4-yl]-acetonitrile 
• 328918-81-6 2-(4-bromophenyl)-4-(chloromethyl)-5-methyl-1,3-oxazole 
• 328918-80-5 4,5-dimethyl-2-(4-bromophenyl)-oxazole oxide 
• 1122-91-4 4-bromo-benzaldehyde 
• 518343-93-6 2-[(biphenyl-4-carbonyl)-amino]-4-[4-(1-carboxy-1-methyl-ethoxy)-phenoxy]butyric acid 
• 518343-91-4 2-acetylamino-2-{2-[4-(1-ethoxycarbonyl-1-methyl-ethoxy)phenoxy]-ethyl}-malonic acid diethyl ester 
• 518343-90-3 2-[4-(2-bromoethoxy)-phenoxy]-2-methyl-propionic acid ethyl ester 

Downstream Products

• 328918-63-4 2-{5-[2-(2-biphenyl-4-yl-5-methyloxazol-4-yl)ethoxy]-2-butylphenoxy}-2-methylpropionic acid 
• 328919-35-3 2-{4-[2-(2-biphenyl-4-yl-5-methyloxazol-4-yl)-ethoxy]-2-methylphenoxy}-2-methylpropionic acid ethyl ester 
• 1445971-29-8 4-[2-(4-benzyloxy-2-butylphenoxy)ethyl]-5-methyl-2-biphenyl-4-yl-oxazole 
• 403612-21-5 4-[2-(4-Benzyloxy-2-propylphenoxy) ethyl]-5-methyl-2-phenyloxazole 
• 328919-42-2 2-{4-[2-(2-biphenyl-4-yl-5-methyloxazol-4-yl)ethoxy]-2-phenethylphenoxy}-2-methylpropionic acid ethyl ester 
• 328919-37-5 2-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-2-cyclohexylmethyl-phenoxy}-2-methyl-propionic acid ethyl ester 

Relevant academic research and scientific papers

Application of the Dakin-West reaction for the synthesis of oxazole-containing dual PPARα/γ agonists

An improved method for the preparation of a series of oxazole-containing dual PPARα/γ agonists is described. A synthetic sequence utilizing a Dakin-West reaction was devised that allows for the introduction of the oxazole ring either late in the synthetic sequence via aminomalonate-derived chemistry or in pivotal SAR intermediates derived from aspartic acid.

Modulators of peroxisome proliferator activated receptors

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented b

Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic acids: A new class of dual PPARα/γ agonists

Propionic acid derivative 8, which was designed and synthesized based on putative pharmacophores of known PPARγ- and PPARα-selective compounds, exhibits potent dual PPARα/γ agonist activity as demonstrated by in vitro binding and dose overlap in the newly